The aims of this grant proposal are: 1) To determine the physiologically important counterregulatory mechanisms responsible for recovery from hypoglycemia in normal man; specifically, we will assess the roles of changes in glucose production and glucose utilization (measured isotopically) and the actions of glucagon, growth hormone, cortisol, adrenomedullary catecholamines, neural norepinephrine, and hepatic autoregulation on these processes. Subcutaneous injection of insulin, rather than intravenous injection or infusion of insulin, will be used to induce hypoglycemia since there is evidence that this model may more accurately reflect the clinical situation. The roles of the factors indicated above will be evaluated by assessing the consequences of pharmacologic blockade of hormone secretion (somatostatin, metyrapone) or action (phentolamine/propranolol) and by assessing changes in glucose production and utilization under conditions in which specific hormone secretion is not possible (e.g., adrenalectomy) or when counterregulation is not stimulated (euglycemic glucose clamp). 2) To characterize and determine the causes of impaired glucose counterregulation in patients with diabetes mellitus; specifically, in addition to identifying the factors important in recovery from hypoglycemia in patients with diabetes (which appear to differ from those of nondiabetic individuals), we will attempt to determine the mechanism(s) responsible for the exaggerated hypoglycemia and posthypoglycemic hyperglycemia that frequently develop in these patients. Further knowledge concerning the defects in glucose counterregulatory mechanisms present in diabetes is needed in view of the growing use of intensified insulin treatment regimens and their associated risk of hypoglycemia. Such knowledge could lead to better selection of patients for these regimens as well as the development of means to diminish the risks for hypoglycemia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
5R01AM020411-09
Application #
3151302
Study Section
Metabolism Study Section (MET)
Project Start
1977-07-01
Project End
1986-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
9
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Gerich, J E (1996) Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 28:404-12
Jansson, P A; Veneman, T; Nurjhan, N et al. (1994) An improved method to calculate adipose tissue interstitial substrate recovery for microdialysis studies. Life Sci 54:1621-4
Consoli, A; Nurjhan, N; Capani, F et al. (1989) Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38:550-7
Nurjhan, N; Consoli, A; Gerich, J (1989) Isotopic estimation of plasma glucose conversion to plasma lactate using [6-3H]glucose and [6-14C]glucose. Proc Soc Exp Biol Med 192:43-6
Consoli, A; Nurjhan, N; Gerich, J (1989) Rates of appearance and disappearance of plasma lactate after oral glucose: implications for indirect-pathway hepatic glycogen repletion in man. Clin Physiol Biochem 7:70-8
Gerich, J E (1989) Oral hypoglycemic agents. N Engl J Med 321:1231-45
Yki-Jarvinen, H; Consoli, A; Nurjhan, N et al. (1989) Mechanism for underestimation of isotopically determined glucose disposal. Diabetes 38:744-51
Kennedy, F P; Gerich, J E (1988) Alpha-glucosidase inhibition and timing of preprandial insulin in patients with insulin-dependent diabetes mellitus (IDDM). Diabetes Res Clin Pract 4:309-12
Opara, E; Kutlu, M; van Haeften, T et al. (1988) Effect of internalization and degradation of insulin on rat adipocyte insulin receptor binding kinetics. Clin Physiol Biochem 6:1-11
Campbell, P J; Bolli, G B; Gerich, J E (1988) Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog. Metabolism 37:34-7

Showing the most recent 10 out of 46 publications